Healthcare / Medical Care FacilitiesTel Aviv
$1110.00
+76.00 (+7.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $10.4M · quality 57.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$172M
P/E
24.1x
↑EV/EBITDA
2073.2x
↑ROE
2.7%
↑Gross Margin
42.8%
↓Debt/Equity
0.24
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.4%
FCF CAGR
-15.8%
FCF margin
21.3%
FCF / Net income
1.43x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $48.9M · net income $7.3M · FCF $10.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $48.9M | $48.9M | $39.8M | $54.3M | $56.0M |
| Net Income | $7.3M | $7.3M | $115.6M | $16.1M | $83.7M |
| EBITDA | $8.3M | $8.3M | $11.7M | $37.7M | $105.9M |
| EPS | — | — | 7.45 | 1.04 | 5.37 |
| Gross Margin | 42.8% | 42.8% | 41.8% | 42.4% | 48.9% |
| Operating Margin | 13.2% | 13.2% | 7.1% | 6.2% | 30.2% |
| Net Margin | 14.9% | 14.9% | 290.4% | 29.7% | 149.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.24 | 0.24 | 0.26 | 0.47 | 0.59 |
| Current Ratio | 2.44 | 2.44 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $10.4M | $10.4M | $27.3M | $1.8M | $17.5M |
| Returns | |||||
| ROE | 2.7% | 2.7% | 25.2% | 4.6% | 23.9% |
| Valuation | |||||
| P/E | 24.13 | 24.13 | 303.01 | 1501.46 | 192.92 |
| EV/EBITDA | 2073.18 | 2073.18 | 2987.40 | 643.35 | 153.77 |
| P/B | 63.61 | 63.61 | 76.38 | 69.15 | 46.16 |
| Growth & Yield | |||||
| Revenue Growth | 22.7% | 22.7% | -26.7% | -3.0% | — |
| EPS Growth | — | — | 618.1% | -80.7% | — |
| Dividend Yield | 2.2% | 2.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-55.3%
Start / end P/E
n/dx → n/dx
EPS bridge
7.45 → n/d
Residual
-57.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.